Andrew J. Armstrong
Title
Cited by
Cited by
Year
Increased survival with enzalutamide in prostate cancer after chemotherapy
HI Scher, K Fizazi, F Saad, ME Taplin, CN Sternberg, K Miller, R de Wit, ...
New England Journal of Medicine 367 (13), 1187-1197, 2012
35072012
Enzalutamide in metastatic prostate cancer before chemotherapy
TM Beer, AJ Armstrong, DE Rathkopf, Y Loriot, CN Sternberg, CS Higano, ...
New England Journal of Medicine 371 (5), 424-433, 2014
19902014
Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers
AJ Armstrong, MS Marengo, S Oltean, G Kemeny, RL Bitting, JD Turnbull, ...
Molecular cancer research 9 (8), 997-1007, 2011
5922011
Prostate cancer, version 1.2016
JL Mohler, AJ Armstrong, RR Bahnson, AV D'Amico, BJ Davis, ...
Journal of the National Comprehensive Cancer Network 14 (1), 19-30, 2016
5222016
Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3
HI Scher, MJ Morris, WM Stadler, C Higano, E Basch, K Fizazi, ...
Journal of Clinical Oncology 34 (12), 1402, 2016
4852016
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis
AJ Armstrong, ES Garrett-Mayer, YCO Yang, R De Wit, IF Tannock, ...
Clinical Cancer Research 13 (21), 6396-6403, 2007
3552007
Prostate cancer, version 2.2014
JL Mohler, PW Kantoff, AJ Armstrong, RR Bahnson, M Cohen, ...
Journal of the National Comprehensive Cancer Network 12 (5), 686-718, 2014
3282014
Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
KL Noonan, S North, RL Bitting, AJ Armstrong, SL Ellard, KN Chi
Annals of oncology 24 (7), 1802-1807, 2013
3232013
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer
AJ Armstrong, E Garrett-Mayer, YC Ou Yang, MA Carducci, I Tannock, ...
Journal of Clinical Oncology 25 (25), 3965-3970, 2007
2772007
Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity
B Shuch, A Amin, AJ Armstrong, JN Eble, V Ficarra, A Lopez-Beltran, ...
European urology 67 (1), 85-97, 2015
2562015
Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer
RL Bitting, AJ Armstrong
Endocrine-related cancer 20 (3), R83-R99, 2013
2502013
Prostate cancer, version 3.2012 featured updates to the NCCN guidelines
JL Mohler, AJ Armstrong, RR Bahnson, B Boston, JE Busby, AV D’Amico, ...
Journal of the National Comprehensive Cancer Network 10 (9), 1081-1087, 2012
2472012
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
AJ Armstrong, S Halabi, T Eisen, S Broderick, WM Stadler, RJ Jones, ...
The Lancet Oncology 17 (3), 378-388, 2016
2102016
Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial
DF Penson, AJ Armstrong, R Concepcion, N Agarwal, C Olsson, L Karsh, ...
Journal of Clinical Oncology 34 (18), 2098-2106, 2016
2072016
Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer
AJ Armstrong, E Garrett-Mayer, R De Wit, I Tannock, M Eisenberger
Clinical Cancer Research 16 (1), 203-211, 2010
1992010
Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer
R Pili, M Häggman, WM Stadler, JR Gingrich, VJ Assikis, A Björk, ...
J. Clin. Oncol. doi 10, 2010
1982010
EpCAM: a new therapeutic target for an old cancer antigen
A Armstrong, SL Eck
Cancer biology & therapy 2 (4), 320-325, 2003
1912003
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial
JC Araujo, GC Trudel, F Saad, AJ Armstrong, YY Evan, J Bellmunt, ...
The lancet oncology 14 (13), 1307-1316, 2013
1822013
Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study
TM Beer, AJ Armstrong, D Rathkopf, Y Loriot, CN Sternberg, CS Higano, ...
European urology 71 (2), 151-154, 2017
173*2017
Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer
AJ Armstrong, MA Eisenberger, S Halabi, S Oudard, DM Nanus, ...
European urology 61 (3), 549-559, 2012
1722012
The system can't perform the operation now. Try again later.
Articles 1–20